Toxicity Genetic Determinants and Response to Azacitidine and Venetoclax in AML

Description

The purpose of this research is to see how certain genetic variations relate to side effects and outcomes experienced while receiving treatment with azacitidine and venetoclax.

Conditions

Leukemia, Myeloid, Acute

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this research is to see how certain genetic variations relate to side effects and outcomes experienced while receiving treatment with azacitidine and venetoclax.

A Prospective Pilot Study of the Genetic Determinants of Toxicity and Response to Azacitidine and Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia Through Evaluation of Polymorphisms in Pharmacokinetic Genes and Venetoclax Levels

Toxicity Genetic Determinants and Response to Azacitidine and Venetoclax in AML

Condition
Leukemia, Myeloid, Acute
Intervention / Treatment

-

Contacts and Locations

Charlotte

Levine Cancer Institute, Charlotte, North Carolina, United States, 28204

Winston-Salem

Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States, 27157

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Written informed consent and HIPAA authorization for release of personal health information.
  • * Age ≥ 18 years of age at the time of enrollment
  • * Confirmed diagnosis of AML
  • * Planned initial treatment with azacitidine and venetoclax
  • * Ability to read and understand the English and/or Spanish language
  • * As determined by the enrolling investigator, ability of the participant to understand and comply with study procedures for the entire length of the study
  • * None

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Wake Forest University Health Sciences,

Brittany Ragon, MD, PRINCIPAL_INVESTIGATOR, Atrium Health Wake Forest Baptist Comprehensive Cancer Center

Study Record Dates

2030-01